Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma

Radiotherapy and Oncology

Volumn 82, Issue 1, 2007, Pages 76-82

  Boucher, Eveline ^a   Garin, Etienne ^b   Guylligomarc'h, Anne ^c   Olivié, Damien ^a   Boudjema, Karim ^d   Raoul, Jean Luc ^a  

^a Department of Medical Oncology ^*

^b CENTRE EUGÈNE MARQUIS   (France)

^c Liver Diseases Unit

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Hepatic artery; Hepatocellular carcinoma; Interventional procedure; Radionuclide study; Therapeutic radiology

Indexed keywords

ALBUMIN TC 99M; ALPHA FETOPROTEIN; ANTIBIOTIC AGENT; CORTICOSTEROID; IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; IODINE 131; MICROSPHERE; RHENIUM 188; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DYSPNEA; FEMALE; FEVER; HUMAN; INJECTION PAIN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG INSUFFICIENCY; MALE; OPEN STUDY; PRIORITY JOURNAL;

AGED; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; IODINE RADIOISOTOPES; IODIZED OIL; LIVER NEOPLASMS; MALE; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33846312444     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2006.11.001     Document Type: Article

References (36)

1. Schafer D.F., and Sorrell M.F. Hepatocellular carcinoma. Lancet 353 (1999) 1253-1257
2. Ikai I., Arii S., Kojiro M., Ichida T., Makuuchi M., Matsuyama Y., et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 101 (2004) 796-802
3. Belghiti J., Hiramatsu K., Benoist S., Massault P., Sauvanet A., and Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 191 (2000) 38-46
4. Capussotti L., Muratore A., Massucco P., Ferrero A., Polastri R., and Bouzari H. Major liver resections for hepatocellular carcinoma on cirrhosis: early and long-term outcomes. Liver Transpl 10 (2004) S64-S68
5. Vivarelli M., Guglielmi A., Ruzzenente A., Cucchetti A., Bellusci R., Cordiano C., et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 240 (2004) 102-107
6. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
7. Shetty K., Timmins K., Brensinger C., Furth E.E., Rattan S., Sun W., et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 10 (2004) 911-918
8. Livraghi T., Giorgio A., Marin G., Salmi A., de Sio I., Bolondi L., et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long term results of percutaneous ethanol injection. Radiology 197 (1995) 101-108
9. Lencioni R., Cioni D., Crocetti L., and Bartolozzi C. Percutaneous ablation of hepatocellular carcinoma: state-of-the-art. Liver Transpl 10 (2004) S91-S97
10. Lin S.M., and Lin D.Y. Percutaneous local ablation therapy in small hepatocellular carcinoma. Chang Gung Med J 26 (2003) 308-314
11. Huo T.I., Huang Y.H., Wu J.C., Lee P.C., Chang F.Y., and Lee S.D. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scand J Gastroenterol 38 (2003) 770-778
12. Bowles B.J., Machi J., Limm W.M., Severino R., Oishi A.J., Furumoto N.L., et al. Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors. Arch Surg 136 (2001) 864-869
13. Giovannini M., Moutardier V., Danisi C., Bories E., Pesenti C., and Delpero J.R. Treatment of hepatocellular carcinoma using percutaneous radiofrequency thermoablation: results and outcomes in 56 patients. J Gastrointest Surg 7 (2003) 791-796
14. Llovet J.M., Real M.I., Montana X., Planas R., Coll S., Aponte J., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
15. Camma C., Schepis F., Orlando A., Albanese M., Shahied L., Trevisani F., et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224 (2002) 47-54
16. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
17. Raoul J.L., Guyader D., Bretagne J.F., Duvauferrier R., Bourguet P., Bekhechi D., et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra arterial iodine-131-iodized oil versus chemoembolisation. J Nucl Med 35 (1994) 1782-1787
18. Raoul J.L., Guyader D., Bretagne J.F., Heautot J.F., Duvauferrier R., Bourguet P., et al. Prospective randomized trial of chemoembolisation versus intra arterial injection of 131-I-labelled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26 (1997) 1156-1161
19. Geschwind J.F., Salem R., Carr B.I., Soulen M.C., Thurston K.G., Goin K.A., et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127 (2004) S194-S205
20. Liu M.D., Uaje M.B., Al-Ghazi M.S., Fields D., Herman J., Kuo J.V., et al. Use of Yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. Am Surg 70 (2004) 947-953
21. Lau W.Y., Leung T.W., Ho S.K., Chan M., Machin D., Lau J., et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353 (1999) 797-801
22. Boucher E., Corbinais S., Rolland Y., Bourguet P., Guyader D., Boudjema K., et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 38 (2003) 1237-1241
23. Raoul J.L., Bourguet P., Bretagne J.F., Duvauferrier R., Coornaert S., Darnault P., et al. Hepatic artery injection of I-131-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 168 (1988) 541-545
24. Okuda K., Ohtsuki T., Obata H., Tomimatsu M., Okazaki N., Hasegawa H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56 (1985) 918-928
25. Prospective validation of CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The cancer of the liver Italian program investigators. Hepatology 2000; 31:840-5.
26. Raoul J.L., Messner M., Boucher E., Bretagne J.F., Campion J.P., and Boudjema K. Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol. Br J Surg 90 (2003) 1379-1383
27. Samuel A.M., Unnikrishnan T.P., Baghel N.S., and Rajashekharrao B. Effect of radioiodine therapy on pulmonary alveolar-capillary membrane integrity. J Nucl Med 36 (1995) 783-787
28. Chung J.W., Park J.H., Han J.K., Choi B.I., Han M.C., Lee H.S., et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198 (1996) 33-40
29. Monsieurs M.A., Bacher K., Brans B., Vral A., De Ridder L., Diercks R.A., et al. Patient dosimetry for 131I-Lipiodol therapy. Eur J Nucl Med Mol Imaging 30 (2003) 554-561
30. Lin M. Radiation pneumonitis caused by Yttrium-90 microspheres: radiologic findings. Am J Roentgenol 162 (1994) 130-132
31. Tajima T., Honda H., Kuroiwa T., Yabuuchi H., Okafuji T., Yosimitsu K., et al. Pulmonary complications after hepatic artery chemoembolization or infusion via the inferior phrenic artery for primary liver cancer. J Vasc Interv Radiol 13 (2002) 893-900
32. Sundram F., Chau T.C., Onkhuudai P., Bernal P., and Padhy A.K. Preliminary results of transarterial rhenium-188 HDD Lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 31 (2004) 250-257
33. De Ruyck K., Lambert B., Bacher K., Gemmel F., De Vos F., Vral A., et al. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma. J Nucl Med 45 (2004) 612-618
34. Lambert B., Bacher K., Defreyne L., Gemmel F., Van Vlierberghe H., Jeong J.M., et al. 188Re-HDD/Lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med 46 (2005) 60-66
35. Lau W.Y., Ho S., Leung T.W., Chan M., Ho R., Johnson P.J., et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40 (1998) 583-592
36. Dancey J.E., Shepherd F.A., Paul K., Sniderman K.W., Houle S., Gabrys J., et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41 (2000) 1673-1681